Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (351-360 of 621) with videos related to

Pageof 63
Sort By:
Journal of Pathology Informatics|February 23, 2023
Automated detection and delineation of lymph nodes in haematoxylin & eosin stained digitised slidesManon Beuque, Derek R Magee, Avishek Chatterjee, et al.
NPJ Precision Oncology|January 13, 2026
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trialTing Pu, Allyson M Peddle, Pratyaksha Wirapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)Manish A Shah, Gyorgy Bodoky, Alexander Starodub, et al.
Blood|October 21, 2004
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaRobert Marcus, Kevin Imrie, Andrew Belch, et al.
The New England Journal of Medicine|July 23, 2004
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerDavid Cunningham, Yves Humblet, Salvatore Siena, et al.
The New England Journal of Medicine|April 9, 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerJuan Valle, Harpreet Wasan, Daniel H Palmer, et al.
BMC Cancer|February 18, 2016
Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective studySing Yu Moorcraft, Elisa Fontana, David Cunningham, et al.
Nature Ecology & Evolution|May 21, 2021
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancerAndrew Woolston, Louise J Barber, Beatrice Griffiths, et al.
Anticancer Research|October 15, 2013
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracilFrancesca V Negri, Cinzia Azzoni, Lorena Bottarelli, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 5, 2026
Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastasesMihaela Rata, Khurum Khan, David J Collins, et al.
Pageof 63

Showing results (351-360 of 621) with videos related to

Sort By:
Pageof 63
Journal of Pathology Informatics|February 23, 2023
Automated detection and delineation of lymph nodes in haematoxylin & eosin stained digitised slidesManon Beuque, Derek R Magee, Avishek Chatterjee, et al.
NPJ Precision Oncology|January 13, 2026
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trialTing Pu, Allyson M Peddle, Pratyaksha Wirapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)Manish A Shah, Gyorgy Bodoky, Alexander Starodub, et al.
Blood|October 21, 2004
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaRobert Marcus, Kevin Imrie, Andrew Belch, et al.
The New England Journal of Medicine|July 23, 2004
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerDavid Cunningham, Yves Humblet, Salvatore Siena, et al.
The New England Journal of Medicine|April 9, 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerJuan Valle, Harpreet Wasan, Daniel H Palmer, et al.
BMC Cancer|February 18, 2016
Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective studySing Yu Moorcraft, Elisa Fontana, David Cunningham, et al.
Nature Ecology & Evolution|May 21, 2021
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancerAndrew Woolston, Louise J Barber, Beatrice Griffiths, et al.
Anticancer Research|October 15, 2013
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracilFrancesca V Negri, Cinzia Azzoni, Lorena Bottarelli, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 5, 2026
Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastasesMihaela Rata, Khurum Khan, David J Collins, et al.
Pageof 63